NCT01449825View on ClinicalTrials.gov

Hepatic Monitoring for Pazopanib

CompletedOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

Pazopanib use

Treatment with pazopanib

DRUG

Use of sunitinib, bevacizumab, or sorafenib

Treatment with any of the three other marketed anti-VEGF drugs: sunitinib, bevacizumab, and sorafenib

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY